Detalhe da pesquisa
1.
The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Br J Cancer
; 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582811
2.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591609
3.
EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation.
Cell Mol Life Sci
; 79(7): 389, 2022 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35773608
4.
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
J Transl Med
; 20(1): 606, 2022 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528667
5.
Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
J Surg Oncol
; 117(2): 236-244, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28787528
6.
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
Br J Cancer
; 113(9): 1254-8, 2015 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26484411
7.
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
BMC Cancer
; 14: 982, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25523272
8.
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
J Pathol
; 231(4): 449-56, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24549645
9.
eEF1A2 promotes PTEN-GSK3ß-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.
Sci Signal
; 17(826): eadh4475, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38442201
10.
RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.
Int J Cancer
; 133(2): 275-85, 2013 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23319376
11.
Poor survival with wild-type TP53 ovarian cancer?
Gynecol Oncol
; 130(3): 565-9, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23800698
12.
PAX2 Expression in Ovarian Cancer.
Int J Mol Sci
; 14(3): 6090-105, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23502471
13.
Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity.
Sci Rep
; 13(1): 21454, 2023 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052873
14.
Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.
Cancer Res
; 83(9): 1503-1516, 2023 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36787106
15.
Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.
J Ovarian Res
; 15(1): 63, 2022 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610648
16.
Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.
Mol Cancer Ther
; 21(7): 1067-1075, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545008
17.
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Am J Pathol
; 177(4): 1611-7, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20802181
18.
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
Gynecol Oncol
; 123(1): 13-8, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21726895
19.
Pathogenesis and Clinical Management of Uterine Serous Carcinoma.
Cancers (Basel)
; 12(3)2020 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32183290
20.
Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.
Sci Rep
; 10(1): 20678, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33244099